Proposed Issue of Securities and Appendix 3B

RNS Number : 1914K

MGC Pharmaceuticals Limited

31 August 2021

 

MGC Pharmaceuticals Ltd.

Appendix 3B Proposed Issue of Securities

31^st August 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ( 'MGC Pharma' or 'the Company') wishes to advise that in accordance with the recently announced US$24M US Supply and Distribution Agreement between AMC Holding Inc ( AMC ) and MGC Pharma, the Company has agreed to issue AMC unlisted options over MGC Pharma shares on satisfaction of an number of key commercial milestones (refer Announcement dated 26 August 2021).

In accordance with ASX Listing Rule 3.10.3 MGC Pharma has lodged an Appendix 3B with the ASX to notify them of the proposed issue, a copy of which is located at the following website:

https://wcsecure.weblink.com.au/pdf/MXC/02414782.pdf  

-Ends-

Authorised for release by David Lim, Company Secretary, for further information, please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	UK PR Advisors - Tavistock Tim Pearson [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels  

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

MSCFIFFETIILVIL